Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Hakozaki, Michiyuki ^a,g   Tajino, Takahiro ^a,g   Konno, Shinichi ^a,g   Kikuchi, Shinichi ^a   Yamada, Hitoshi ^a,g   Yanagisawa, Michiro ^b,g   Nishida, Jun ^c,g   Nagasawa, Hiroyuki ^d,g   Tsuchiya, Takashi ^e,g   Ogose, Akira ^f,g   Abe, Masafumi ^a   Hojo, Hiroshi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d AKITA UNIVERSITY   (Japan)

^e YAMAGATA UNIVERSITY   (Japan)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^g Tohoku Musculoskeletal Tumor Society   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYCLOOXYGENASE 2; ETODOLAC; NEUROFIBROMIN; CASPASE; CYCLOOXYGENASE 2 INHIBITOR; PTGS2 PROTEIN, HUMAN;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL STRAIN FMS 1; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; ENZYME ACTIVATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; TUMOR CELL LINE; TUMOR LOCALIZATION; TUMOR VOLUME; ADOLESCENT; AGED; CELL SHAPE; DNA FRAGMENTATION; DRUG EFFECTS; ENZYMOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NERVE SHEATH TUMOR; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASPASE INHIBITORS; CASPASES; CELL LINE, TUMOR; CELL SHAPE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DNA FRAGMENTATION; ENZYME ACTIVATION; ETODOLAC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NERVE SHEATH NEOPLASMS; YOUNG ADULT;

EID: 84895534286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088035     Document Type: Article

References (53)

1. Nielsen GP, Antonescu CR, Lothe RA (2013) Malignant peripheral nerve sheath tumour. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone, 4th ed. Lyon: IARC. 187-189.
2. Weiss SW, Goldblum JR (2007) Malignant tumors of the peripheral nerves. In: Weiss SW, Goldblum JR, editors. Enzinger and Weiss's soft tissue tumors, 5th ed. Philadelphia: Mosby/Elsevier. 903-917.
3. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN (2008) Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 97: 340-349. (Pubitemid 351358582)
4. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120. (Pubitemid 28231490)
5. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, et al. (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073. (Pubitemid 28418937)
6. Endo M, Matsumura T, Yamaguchi T, Yamaguchi U, Morimoto Y, et al. (2006) Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol 37: 471-476.
7. Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, et al. (2008) COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol 30: 507-512.
8. Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N (2009) Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res 467: 2932-2938.
9. Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN (2010) Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med 150: 237-242.
10. Lee CH, Roh JW, Choi JS, Kang S, Park IA, et al. (2011) Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer 21: 668-672.
11. Wang D, DuBois RN (2006) Prostaglandins and cancer. Gut 55: 115-122. (Pubitemid 41820645)
12. Moalic S, Liagre B, Le Bail JC, Beneytout JL (2001). Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 18: 533-540.
13. Moalic-Juge S, Liagre B, Duval R, Corbiere C, Bianchi A, et al. (2002) The antiapoptotic property of NS-398 at high dose can be mediated in part through NF-kappaB activation, hsp70 induction and a decrease in caspase-3 activity in human osteosarcoma cells. Int J Oncol 20: 1255-1262.
14. Yamashita H, Osaki M, Honjo S, Yoshida H, Teshima R, et al. (2003) A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res 23: 4671-4676. (Pubitemid 38173883)
15. Naruse T, Nishida Y, Hosono K, Ishiguro N (2006) Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27: 584-592. (Pubitemid 43378898)
16. Hakozaki M, Hojo H, Kikuchi S, Abe M (2007) Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1). Oncol Rep 17: 169-173.
17. Masi L, Recenti R, Silvestri S, Pinzani P, Pepi M, et al. (2007) Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol 15: 70-76. (Pubitemid 46673320)
18. Liu B, Shi ZL, Feng J, Tao HM (2008) Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 32: 494-501.
19. Schrage YM, Machado I, Meijer D, Briaire-de Bruijn I, van den Akker BE, et al. (2010) COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Eur J Cancer 46: 616-624.
20. Gendy AS, Lipskar A, Glick RD, Steinberg BM, Edelman M, et al. (2011) Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. J Pediatr Surg 46: 108-114.
21. Reed S, Li H, Li C, Lin J (2011) Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells. Biochem Biophys Res Commun 407: 450-455.
22. Hakozaki M, Hojo H, Sato M, Tajino T, Yamada H, et al. (2006) Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2. Anticancer Res 26: 3393-3401. (Pubitemid 44701514)
23. Hakozaki M, Hojo H, Sato M, Tajino T, Yamada H, et al. (2009) Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2. Virchows Arch 455: 517-526.
24. Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP (2003) Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 25: 282-285. (Pubitemid 36506213)
25. Yamashita H, Osaki M, Ardyanto TD, Osaki M, Yoshida H, et al. (2004) Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase. Int J Mol Med 14: 565-570.
26. Herceg ME, Tsiatis AC, Halpern JL, Holt GE, Schwartz HS, et al. (2009) Cyclooxygenase 2 expression in soft tissue leiomyosarcoma. Anticancer Res 29: 2913-2917.
27. Nakagawa SA, Lopes A, Lopes de Carvalho A, Rossi BM, Werneck da Cunha I, et al. (2010) Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am 92: 1738-1746.
28. Carmody Soni EE, Miller BJ, Scarborough MT, Reith J, Parker Gibbs C (2011) Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma. Oncol Rep 26: 1513-1517.
29. Sutton KM, Wright M, Fondren G, Towle CA, Mankin HJ (2004) Cyclooxygenase-2 expression in chondrosarcoma. Oncology 66: 275-280. (Pubitemid 38822796)
30. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, et al. (2006) Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 107: 1065-1074. (Pubitemid 44291156)
31. Okada K, Hasegawa T, Tajino T, Hotta T, Yanagisawa M, et al. (2007) Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multi-institution TMTS study of 56 cases in Northern Japan. Ann Surg Oncol 14: 597-604. (Pubitemid 46175305)
32. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL (1998) Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42: 351-360. (Pubitemid 28502782)
33. Baehring JM, Betensky RA, Batchelor TT (2003) Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology 61: 696-698. (Pubitemid 37082610)
34. Salas S, Bui B, Stoeckle E, Terrier P, Ranchere-Vince D, et al. (2009) Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database. Ann Oncol 20: 1127-1135.
35. Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, et al. (2011) Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res 17: 3771-3782.
36. Mazhar D, Ang R, Waxman J (2006) COX inhibitors and breast cancer. Br J Cancer 94: 346-350. (Pubitemid 43237558)
37. Bernard MP, Bancos S, Sime PJ, Phipps RP (2008) Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 14: 2051-2060.
38. Ola MS, Nawaz M, Ahsan H (2011) Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351: 41-58.
39. Liu XH, Yao S, Kirschenbaum A, Levine AC (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245-4249. (Pubitemid 28450018)
40. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F (2002) Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62: 4903-4908. (Pubitemid 34984412)
41. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ (2002) COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 35: 552-559. (Pubitemid 34183958)
42. Li M, Wu X, Xu XC (2001) Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7: 1010-1016. (Pubitemid 32708740)
43. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, et al. (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403. (Pubitemid 30212792)
44. Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686. (Pubitemid 28083803)
45. Jendrossek V (2013) Targeting apoptosis pathways by celecoxib in cancer. Cancer Lett 332: 313-324.
46. Kasper B, Ho AD, Egerer G (2005) A new therapeutic approach in patients with advanced sarcoma. Int J Clin Oncol 10: 438-440. (Pubitemid 41821530)
47. McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8: e1001098.
48. Brater DC, Lasseter KC (1989) Profile of etodolac: pharmacokinetic evaluation in special populations. Clin Rheumatol 8, Suppl 1: 25-35. (Pubitemid 20122966)
49. Fletcher CD, Dal Cin P, de Wever I, Mandahl N, Mertens F, et al. (1999) Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. Am J Pathol 154: 1841-1847. (Pubitemid 29262867)
50. Fletcher CDM (2000) Peripheral neuroectodermal tumors. In: Fletcher CDM, editor. Diagnostic histopathology of tumors, 2nd ed. London: Churchill Livingstone. 1695-1698.
51. (1998) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45: 575-578.
52. Enneking WF, Maale GE (1981) The effect of inadvertent tumor contamination of wounds during the surgical resection of musculoskeletal neoplasms. Cancer 62: 1251-1256.
53. Bajorath J (1999) Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface. J Comput Aided Mol Des 13: 409-418.